Lins R L, Elseviers M M, Daelemans R, Arnouts P, Billiouw J-M, Couttenye M, Gheuens E, Rogiers P, Rutsaert R, Van der Niepen P, De Broe M E
Department of Nephrology-Hypertension, ACZA Campus Stuivenberg, Lange Beeldekensstraat 267, B-2060 Antwerpen, Belgium.
Nephrol Dial Transplant. 2004 Sep;19(9):2282-8. doi: 10.1093/ndt/gfh364. Epub 2004 Jul 20.
A prognostic scoring system for hospital mortality in acute renal failure (Stuivenberg Hospital Acute Renal Failure, SHARF score) was developed in a single-centre study. The scoring system consists of two scores, for the time of diagnosis of acute renal failure (ARF) and for 48 h later, each originally based on four parameters (age, serum albumin, prothrombin time and heart failure). The scoring system was now tested and adapted in a prospective study.
The study involved eight intensive care units. We studied 293 consecutive patients with ARF in 6 months. Their mortality was 50.5%. The causes of ARF were medical in 184 (63%) patients and surgical in 108 (37%). In the latter group, 74 (69%) patients underwent cardiac and 19 (18%) vascular surgery.
As the performance of the original SHARF scores was much lower in the multicentre study than in the original single-centre study, we re-analysed the multicentre data to customize the original model for the population studied. The independent variables were the score developed in the original study plus all additonal parameters that were significant on univariate analysis. The new multivariate analysis revealed an additional subset of three parameters for inclusion in the model (serum bilirubin, sepsis and hypotension). For the modified SHARF II score, r(2) was 0.27 at 0 and 0.33 at 48 h, respectively, the receiver operating characteristic (ROC) values were 0.82 and 0.83, and the Hosmer-Lemeshow goodness-of-fit P values were 0.19 and 0.05.
After customizing and by using two scoring moments, this prediction model for hospital mortality in ARF is useful in different settings for comparing groups of patients and centres, quality assessment and clinical trials. We do not recommend its use for individual patient prognosis.
急性肾衰竭医院死亡率的预后评分系统(斯图伊芬贝格医院急性肾衰竭,SHARF评分)是在一项单中心研究中开发的。该评分系统由两个评分组成,分别针对急性肾衰竭(ARF)诊断时和48小时后,每个评分最初基于四个参数(年龄、血清白蛋白、凝血酶原时间和心力衰竭)。该评分系统现在前瞻性研究中进行了测试和调整。
该研究涉及八个重症监护病房。我们在6个月内研究了293例连续的ARF患者。他们的死亡率为50.5%。ARF的病因在184例(63%)患者中为内科性,在108例(37%)患者中为外科性。在后一组中,74例(69%)患者接受了心脏手术,19例(18%)患者接受了血管手术。
由于在多中心研究中原始SHARF评分的表现远低于原始单中心研究,我们重新分析了多中心数据,以便为所研究的人群定制原始模型。自变量是原始研究中开发的评分加上单变量分析中有显著意义的所有其他参数。新的多变量分析揭示了模型中要纳入的另外三个参数子集(血清胆红素、脓毒症和低血压)。对于改良的SHARF II评分,r(2)在0时为0.27,在48小时时为0.33,受试者操作特征(ROC)值分别为0.82和0.83,Hosmer-Lemeshow拟合优度P值分别为0.19和0.05。
经过定制并使用两个评分时间点后,这个ARF医院死亡率预测模型在不同环境下对于比较患者组和中心、质量评估及临床试验是有用的。我们不建议将其用于个体患者的预后评估。